

Scott Fung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7420941/publications.pdf>

Version: 2024-02-01

27
papers

2,069
citations

567247

15
h-index

642715

23
g-index

29
all docs

29
docs citations

29
times ranked

2530
citing authors

#	ARTICLE	IF	CITATIONS
1	Getting to HBV cure: The promising paths forward. <i>Hepatology</i> , 2022, 76, 233-250.	7.3	70
2	HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. <i>Viruses</i> , 2022, 14, 657.	3.3	26
3	Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 51-60.	2.0	1
4	Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 942-950.	2.0	16
5	IDDF2021-ABS-0077...Efficacy and safety of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in east asian chronic hepatitis B patients following 5-years of treatment. , 2021, , .		2
6	IDDF2021-ABS-0080...96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity. , 2021, , .		0
7	Melanoma of the Liver and Gut. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 247-248.	0.3	0
8	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 441-453.	8.1	85
9	IDDF2020-ABS-0060...Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF. , 2020, , .		0
10	IDDF2020-ABS-0061...Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB). , 2020, , .		0
11	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019, 9, 10529.	3.3	12
12	Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). <i>Gut</i> , 2019, 68, 2206-2213.	12.1	109
13	Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B. <i>Liver International</i> , 2019, 39, 1418-1427.	3.9	4
14	96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681.	3.7	291
15	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 68, 431-440.	3.7	147
16	IDDF2018-ABS-0106...Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0
17	Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3487-3497.	2.3	45
18	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. <i>Journal of Hepatology</i> , 2017, 66, 11-18.	3.7	52

#	ARTICLE	IF	CITATIONS
19	Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0151829.	2.5	284
20	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2016, 14, 1821-1830.e6.	4.4	61
21	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 185-195.	8.1	336
22	Combination of Tenofovir Disoproxil Fumarate and Peginterferon α -2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology, 2016, 150, 134-144.e10.	1.3	284
23	Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials. PLoS ONE, 2015, 10, e0121632.	2.5	17
24	Metastatic Hepatocellular Carcinoma in a Patient with Crohn's Disease Treated with Azathioprine and Infliximab: A Case Report and Literature Review. Case Reports in Gastrointestinal Medicine, 2014, 2014, 1-4.	0.3	6
25	Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B. Gastroenterology, 2014, 146, 980-988.e1.	1.3	145
26	Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. BMJ Case Reports, 2014, 2014, bcr2014208117-bcr2014208117.	0.5	9
27	The Utility of Polysporin Ointment in the Eradication of Methicillin-Resistant Staphylococcus aureus Colonization: A Pilot Study. Infection Control and Hospital Epidemiology, 2000, 21, 653-655.	1.8	33